Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Gelderblom

Showing results (211-220 of 251) with videos related to

Pageof 26
Sort By:
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 16, 2014
Isolated hepatic perfusion with oxaliplatin combined with 100 mg melphalan in patients with metastases confined to the liver: A phase I studyL B J van Iersel, E M de Leede, A L Vahrmeijer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 7, 2012
Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patientsD B Y Fontein, D Houtsma, E T M Hille, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 29, 2008
Isolated hepatic melphalan perfusion of colorectal liver metastases: outcome and prognostic factors in 154 patientsL B J van Iersel, H Gelderblom, A L Vahrmeijer, et al.
European Journal of Cancer (Oxford, England : 1990)|November 13, 2013
Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic studyH Gelderblom, J Y Blay, B M Seddon, et al.
ESMO Open|September 12, 2021
Priorities and preferences of advanced soft tissue sarcoma patients starting palliative chemotherapy: baseline results from the HOLISTIC studyE Younger, R L Jones, D den Hollander, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 18, 2010
Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upP C W Hogendoorn, , N Athanasou, et al.
European Journal of Cancer (Oxford, England : 1990)|December 15, 2015
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II studyC M L Driessen, J P de Boer, H Gelderblom, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 30, 2010
Management of isolated nonresectable liver metastases in colorectal cancer patients: a case-control study of isolated hepatic perfusion with melphalan versus systemic chemotherapyL B J van Iersel, M Koopman, C J H van de Velde, et al.
Breast Cancer Research and Treatment|July 12, 2013
CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trialV O Dezentjé, R H N van Schaik, J M Vletter-Bogaartz, et al.
Nature|April 15, 2026
Prospective evaluation of genomics-guided off-label treatmentK Verkerk, A C Spiekman, S F Haj Mohammad, et al.
Pageof 26

Showing results (211-220 of 251) with videos related to

Sort By:
Pageof 26
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 16, 2014
Isolated hepatic perfusion with oxaliplatin combined with 100 mg melphalan in patients with metastases confined to the liver: A phase I studyL B J van Iersel, E M de Leede, A L Vahrmeijer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 7, 2012
Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patientsD B Y Fontein, D Houtsma, E T M Hille, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 29, 2008
Isolated hepatic melphalan perfusion of colorectal liver metastases: outcome and prognostic factors in 154 patientsL B J van Iersel, H Gelderblom, A L Vahrmeijer, et al.
European Journal of Cancer (Oxford, England : 1990)|November 13, 2013
Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic studyH Gelderblom, J Y Blay, B M Seddon, et al.
ESMO Open|September 12, 2021
Priorities and preferences of advanced soft tissue sarcoma patients starting palliative chemotherapy: baseline results from the HOLISTIC studyE Younger, R L Jones, D den Hollander, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 18, 2010
Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upP C W Hogendoorn, , N Athanasou, et al.
European Journal of Cancer (Oxford, England : 1990)|December 15, 2015
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II studyC M L Driessen, J P de Boer, H Gelderblom, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 30, 2010
Management of isolated nonresectable liver metastases in colorectal cancer patients: a case-control study of isolated hepatic perfusion with melphalan versus systemic chemotherapyL B J van Iersel, M Koopman, C J H van de Velde, et al.
Breast Cancer Research and Treatment|July 12, 2013
CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trialV O Dezentjé, R H N van Schaik, J M Vletter-Bogaartz, et al.
Nature|April 15, 2026
Prospective evaluation of genomics-guided off-label treatmentK Verkerk, A C Spiekman, S F Haj Mohammad, et al.
Pageof 26